Combined market capitalization of Celltrion Group, Samsung BioLogics and Hanmi Pharma Group took up nearly half of the market cap of healthcare companies listed on the Korean stock markets last year, a report said.

The report, released by Samsung Securities Tuesday, also showed the healthcare sector also accounted for 6 percent of the total stock markets.

According to the report, the number of companies with more than 2 trillion won ($1.79 billion) in market cap, and their share in the total market cap are both increasing.

The proportion of healthcare sector in the Korean stock markets grew since Samsung BioLogics went public on the main bourse Kospi in November 2016, and Celltrion Healthcare, on the secondary Kosdaq in July 2017.

On Kospi, pharmaceutical firms with more than 2 trillion won market cap include Samsung BioLogics with 25.7 trillion won, Hanmi Science with 5.94 trillion won, Hanmi Pharm with 5.71 trillion won, Green Cross with 2.55 trillion won, and Yuhan with 2.48 trillion won.

On Kosdaq, those with more than 2 trillion won market cap include Celltrion with 20.9 trillion won, Celltrion Healthcare with 7.83 trillion won, Medytox with 2.5 trillion won, ViroMed with 2.88 trillion won and Hugel Biopharmaceuticals with 2.38 trillion won.

The proportion of healthcare sector in the total market cap went up to 6 percent in late 2016 from 2 percent in late 1986, and it will continue to grow, analysts said.

“With an advancement of industries, the shares of IT and healthcare sectors have drastically increased. In the mid- and long-term, pharmaceuticals and biopharmaceuticals are expected to keep expanding on the Korean stock markets,” the report said.